Characteristics of the patient population
| Characteristics . | Patients with second cancer . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total cohort . | Brain tumor . | AML/MDS* . | HD . | NHL . | Sarcoma . | Thyroid cancer . | Parotid tumors . | Other solid tumors . | |
| No. of patients | 8831 | 19 | 14 | 2 | 6 | 4 | 4 | 4 | 8 |
| Male sex, % of cohort | 57% | 37% | 71% | 50% | 67% | 0% | 50% | 50% | 50% |
| Age at diagnosis of ALL | |||||||||
| Median, y | 4.7 | 3.8 | 4.8 | 9.0 | 5.6 | 8.0 | 2.9 | 2.9 | 11.8 |
| Range, y | 0-20.8 | 1.3-15.5 | 1.6-15.8 | 3.8-14.3 | 1.3-8.1 | 1.9-14.1 | 1.5-4.0 | 1.8-14.9 | 0.2-17.4 |
| 5 y or less, % of cohort | 54% | 68% | 57% | 50% | 50% | 50% | 100% | 75% | 13% |
| Time to 2nd neoplasms, y | |||||||||
| Median | — | 7.1 | 3.1 | 2.3 | 3.1 | 3.6 | 9.7 | 8.9 | 7.9 |
| Range | — | 3.9-13.0 | 0.9-10.7 | 1.9-2.6 | 1.5-12.7 | 2.4-5.6 | 5.5-11.8 | 5.2-15.8 | 1.1-15.7 |
| Treatment, % of cohort | |||||||||
| Cyclophosphamide | 79% | 68% | 85% | 100% | 67% | 100% | 100% | 75% | 86% |
| Anthracyclines | 79% | 68% | 85% | 100% | 67% | 100% | 100% | 75% | 86% |
| Radiation | 38% | 63% | 50% | 50% | 17% | 50% | 50% | 75% | 63% |
| Characteristics . | Patients with second cancer . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total cohort . | Brain tumor . | AML/MDS* . | HD . | NHL . | Sarcoma . | Thyroid cancer . | Parotid tumors . | Other solid tumors . | |
| No. of patients | 8831 | 19 | 14 | 2 | 6 | 4 | 4 | 4 | 8 |
| Male sex, % of cohort | 57% | 37% | 71% | 50% | 67% | 0% | 50% | 50% | 50% |
| Age at diagnosis of ALL | |||||||||
| Median, y | 4.7 | 3.8 | 4.8 | 9.0 | 5.6 | 8.0 | 2.9 | 2.9 | 11.8 |
| Range, y | 0-20.8 | 1.3-15.5 | 1.6-15.8 | 3.8-14.3 | 1.3-8.1 | 1.9-14.1 | 1.5-4.0 | 1.8-14.9 | 0.2-17.4 |
| 5 y or less, % of cohort | 54% | 68% | 57% | 50% | 50% | 50% | 100% | 75% | 13% |
| Time to 2nd neoplasms, y | |||||||||
| Median | — | 7.1 | 3.1 | 2.3 | 3.1 | 3.6 | 9.7 | 8.9 | 7.9 |
| Range | — | 3.9-13.0 | 0.9-10.7 | 1.9-2.6 | 1.5-12.7 | 2.4-5.6 | 5.5-11.8 | 5.2-15.8 | 1.1-15.7 |
| Treatment, % of cohort | |||||||||
| Cyclophosphamide | 79% | 68% | 85% | 100% | 67% | 100% | 100% | 75% | 86% |
| Anthracyclines | 79% | 68% | 85% | 100% | 67% | 100% | 100% | 75% | 86% |
| Radiation | 38% | 63% | 50% | 50% | 17% | 50% | 50% | 75% | 63% |
HD indicates Hodgkin disease.
Does not include the patients with chronic myelogenous leukemia (n = 1) and chronic myelomonocytic leukemia (n = 1).